These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

871 related items for PubMed ID: 18200329

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP, Söderström M, Rouland JF, Malecaze F.
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oculohypotensive effects of foeniculum vulgare in experimental models of glaucoma.
    Agarwal R, Gupta SK, Agrawal SS, Srivastava S, Saxena R.
    Indian J Physiol Pharmacol; 2008 Feb; 52(1):77-83. PubMed ID: 18831355
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Latanoprost: new preparation. Antiglaucoma eye drops that can change the colour of the iris.
    Prescrire Int; 1998 Dec; 7(38):166-8. PubMed ID: 10848045
    [Abstract] [Full Text] [Related]

  • 13. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
    Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC, Xplore Observation Group.
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range.
    Varma R, Hwang LJ, Grunden JW, Bean GW, Sultan MB.
    Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An evaluation of the rate of nonresponders to latanoprost therapy.
    Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, Carassa R, Mastropasqua L, Quaranta L, Marchini G, Ratiglia R, Orzalesi N.
    J Glaucoma; 2006 Jun; 15(3):238-43. PubMed ID: 16778647
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, Mano H, Kawazu K.
    PLoS One; 2016 Jun; 11(7):e0158797. PubMed ID: 27383260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.